The Committee discusses Lexicon (LXRX) Pharmaceuticals’ New Drug Application #210934, for sotagliflozin oral tablet, as an adjunct to insulin therapy, to improve glycemic control in adults with Type 1 diabetes mellitus and chronic kidney disease in a meeting being held at FDA Silver Spring, MD Headquarters on October 31 at 8:30 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LXRX:
- Lexicon announces new analysis of Phase 3 SCORED trial
- Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
- Lexicon completes screening in Phase 2B progress study of LX9211
- Lexicon signs licensing agreement with Viatris for sotagliflozin
- Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
